The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bobrov A.E.

Moskovskiĭ nauchno-issledovatel'skiĭ institut psikhiatrii, Moskva

Krasnoslobodtseva L.A.

Kafedra psikhiatrii fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Mutnykh E.M.

Fakul'tet usovershenstvovaniia vracheĭ Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Procognitive effects of fluvoxamine: preliminary data

Authors:

Bobrov A.E., Krasnoslobodtseva L.A., Mutnykh E.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6): 43‑49

DOI: 10.17116/jnevro20181186143

Read: 9789 times

Download PDF (RU)
Contact the author
Table of contents

PROCOGNITIVE EFFECTS OF FLUVOXAMINE: PRELIMINARY DATA
PROCOGNITIVE EFFECTS OF FLUVOXAMINE: PRELIMINARY DATA

To cite this article:

Bobrov AE, Krasnoslobodtseva LA, Mutnykh EM. Procognitive effects of fluvoxamine: preliminary data. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6):43‑49. (In Russ.)
https://doi.org/10.17116/jnevro20181186143

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
Arte­rial hype­rtension is an oxidative stress, as a pathogenetic target for the treatment of chro­nic cere­brovascular insu­fficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90
A personalized approach to the treatment of chro­nic tension headache and como­rbid mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57
Cognitive vascular diso­rders and morphometric para­meters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95
Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10
The study of the beha­vioral reactions and dura­tion of ultrasonic voca­lization in rats from fema­les stre­ssed during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):117-123
The state of mental health of migrant workers and citi­zens of the Russian Fede­ration: A comparative analysis as illu­strated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
Expe­rience with the use of amitriptyline for chro­nic pelvic pain asso­ciated with endo­metriosis. Russian Journal of Human Reproduction. 2025;(1):86-93
Abstract:

Objective. To identify and investigate procognitive effects of fluvoxamine. Material and methods. A prospective non-comparative trial of fluvoxamine was carried out in 50 patients in the remission phase of recurrent depressive disorder. To assess the efficacy of therapy, the Stroop color and word test, the Revised version of Addenbrooke’s Cognitive Examination, the Frontal Assessment Battery, the Hamilton Depression Scale and the Social Adaptation Self-Evaluation Scale were used. Fluvoxamine was administered at doses of 50—150 mg/day for 24-weeks. Results. There were the improvement of executive functions, including selective attention and inhibitory control, and recovery of verbal fluency. The procognitive effect of fluvoxamine was dose-dependent and was related to the reduction of residual depressive symptoms. Conclusion. Fluvoxamine has procognitive effects, stabilizes remission and improves social adaptation of the patients.

Keywords:

fluvoxamine
cognitive functions
depression
neurocognitive assessment techniques

Authors:

Bobrov A.E.

Moskovskiĭ nauchno-issledovatel'skiĭ institut psikhiatrii, Moskva

Krasnoslobodtseva L.A.

Kafedra psikhiatrii fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Mutnykh E.M.

Fakul'tet usovershenstvovaniia vracheĭ Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Close metadata

References:

  1. Phillips WJ, Hine DW, Thorsteinsson EB. Implicit cognition and depÂression: a meta-analysis. Clinical Psychology Review. 2010;30(6):691-709. https://doi.org/10.1016/j.cpr.2010.05.002
  2. Lee RSC, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. Journal of Affective Disorders. 2012;140(2):113-124. https://doi.org/10.1016/j.jad.2011.10.023
  3. Shmukler AB. Cognitive impairment in depressive syndrom. Social’naja i klinicheskaja psihiatrija. 2016;26(1):72-76. (In Russ.)
  4. Mocking RJ. Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study. BMJ Open. 2016;6(3):e009510 https://doi.org/10.1136/bmjopen-2015-009510
  5. Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: A systematic review and meta-analysis. Neuropsychology. 2017;31(1):52-72. https://doi.org/10.1037/neu0000319
  6. Alexopoulos GS, Manning K, Kanellopoulos D. Cognitive Control, Reward Related Decision Making and Outcomes of Late-Life Depression Treated with an Antidepressant. Psychological Medicine. 2015;45(14):3111-3120. https://doi.org/10.1017/s0033291715001075
  7. Bobrov AE, Kursakov AA. Clinical polymorphism of depression and cognitive deficit. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(8):19-24. (In Russ.)
  8. Bortolato B, Miskowiak KW, Köhler CA. Cognitive remission: a novel objective for the treatment of major depression? BMC Medicine. 2016;14:9. https://doi.org/10.1186/s12916-016-0560-3
  9. McIntyre RS, Xiao HX, Syeda K. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015;29(7):577-589. https://doi.org/10.1007/s40263-015-0263-x
  10. Daviss WB. A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. Journal of Child and Adolescent Psychopharmacology. 2008;18(6):565-571. https://doi.org/10.1089/cap.2008.032
  11. Cowen P, Sherwood A. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. Journal of Psychopharmacology. 2013;27(7):575-583. https://doi.org/10.1177/0269881113482531
  12. Solé B, Jiménez E, Martinez-Aran A. Cognition as a target in major depression: new developments. European Neuropsychopharmacology. 2015;25(2): 231-247. https://doi.org/10.1016/j.euroneuro.2014.12.004
  13. Kourrich S, Su T-P, Fujimoto M. The sigma-1 receptor: roles in neuronal plasticity and disease. Trends in Neurosciences. 2012;35(12):762-771. https://doi.org/10.1016/j.tins.2012.09.007
  14. Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. Journal of Pharmacological Sciences. 2015;127(1):6-9. https://doi.org/10.1016/j.jphs.2014.11.010
  15. Hindmarch I, Hashimoto K. Cognition and depression: the effects of ï¬‚uvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacology: Clinical and Experimental. 2010;25(3):193-200. https://doi.org/10.1002/hup.1106
  16. Stahl S. Antidepressant treatment of psychotic Major Depression: potential role of the sigma receptor. CNS Spectrums. 2005;10(4):319-323. https://doi.org/10.1017/s1092852900022641
  17. Hamilton M. The Hamilton Rating Scale for Depression, eds. Assessment of Depression. Berlin Heidelberg: Springer-Verlag; 1986. https://doi.org/10.1007/978-3-642-70486-4_14
  18. Kokh K. Effekt Strupa, ego psikhometricheskie svoistva i ispol’zovanie v kachestve sredstva otsenki. Voprosy psikhologii. 2003;11(6):136-143. (In Russ.)
  19. Williams JMG, MacLeod C, Mathews A. The Emotional Stroop Task and Psychopathology. Psychological Bulletin. 1996;120(1):3-24. https://doi.org/10.1037//0033-2909.120.1.3
  20. Ivanets NN, Tsarenko DM, Bobrova MA, Kursakov AA, Starostina EG, Bobrov AE. Use of Addenbrooke’s cognitive examination-revised to evaluate the patients’ state in general medical practice. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1):52-57. (In Russ.) https://doi.org/10.14412/2074-2711-2012-362
  21. Mathuranath PS, Nestor PJ, Berrios GE. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology. 2000;55(11):1613-1620. https://doi.org/10.1212/01.wnl.0000434309.85312.19
  22. Dubois B, Slachevsky A, Litvan I. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;11(55):1621-1626. https://doi.org/10.1212/wnl.55.11.1621
  23. Bosc M, Dubini A, Polin V. Suppl Development and validation of social functioning scale, the Soscial Adaptation Self-evaluation Scale. European Neuropsychopharmacology. 1997;7(1):57-70. https://doi.org/10.1016/s0924-977x(97)00420-3
  24. Bobrov A, Krasnoslobodtseva L, Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. Journal of Psychiatry. 2017;20:5. https://doi.org/10.4172/2378-5756.1000417
  25. Bobrov AE, Mutnykh EM, Krasnoslobodtseva LA. Comparison of antipsychotics (quetiapin, aripiprazole and haloperidol): therapeutic dynamics of psychopathological and neurocognitive symptomatology with patients affected with schizoaffective disorder. Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2014;1:39-43. (In Russ.)
  26. Bobrov AE, Tsarenko DM, Kursakov AA, Dovzhenko TV. Anxiety-depressive disorders and cognitive impairment in patients of the primary level of health care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(2):14-19. (In Russ.)
  27. Rotomskis A, Margevičiūtė R, Germanavičius A. Differential diagnosis of depression and Alzheimer’s disease with the Addenbrooke’s Cognitive Examination-Revised (ACE-R). BMC Neurology. 2015;15(1):57. https://doi.org/10.1186/s12883-015-0315-3
  28. Edwards S, Brice C, Craig C. Effects of caffeine, practice, and mode of presentation on Stroop task performance. Pharmacology Biochemistry and Behavior. 1996;54(2):309-315. https://doi.org/10.1016/0091-3057(95)02116-7
  29. Salinsky MC, Storzbach D, Dodrill CB. Test-retest bias, reliability, and regression equations for neuropsychological measures repeated over a 12 16-week period. Journal of the International Neuropsychological Society. 2001;7(5): 597-605. https://doi.org/10.1017/s1355617701755075
  30. Lemay S, Bédard M-A, Rouleau I. Executive Tests in Middle-Aged to Elderly Subjects. The Clinical Neuropsychologist. 2004;18(2):284-302. https://doi.org/10.1080/13854040490501718
  31. Vaney N, Dixit A, Goyal A. Effect of caffeine on information processing: evidence from stroop task. Indian Journal of Psychological Medicine. 2012;34(3):218-222. https://doi.org/10.4103/0253-7176.106013
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.